Control Bionics Ltd. (AU:CBL) has released an update. Control Bionics Ltd is set to showcase its innovative medical devices at the Coffee Microcaps Morning Meeting with CEO Jeremy Steele leading the ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Control Bionics Ltd. has announced ...

Control Bionics (ASX:CBL) has officially launched its NeuroNode Only sales model in the US following recent issuance of US Medicare reimbursement code E2513 under the Healthcare Common Procedure ...

Control Bionics progresses, expanding its market reach and product use NeuroNode Only sales model launched in US following Medicare reimbursement code NeuroStrip gaining traction in sports science, ...

Revenue: AU$6.14m (up 15% from FY 2024). Net loss: AU$6.11m (loss widened by 3.3% from FY 2024). AU$0.023 loss per share. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% ...

Control Bionics is on track for record revenue in FY25 driven by strong performance in the US and growth in Australia. Commercialisation of its new NeuroStrip wearable tech progressing across sports ...

Control Bionics is on track for record revenue in FY25 driven by strong performance in the US and growth in Australia. Don't miss out on the headlines from Stockhead. Followed categories will be added ...

Control Bionics Ltd. ( ($AU:CBL) ) just unveiled an announcement. Control Bionics has completed the acquisition of 100% of U.S.-based Neuro Elite ...